Navigation Links
MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation
Date:9/22/2009

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Twelve-month data from EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study high-risk registry arm presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco show that high risk patients with functional mitral regurgitation (MR) following valve repair with the MitraClip(R) system showed a reduction in mitral annular dimension, improvement in heart function and a reduction in hospitalization for congestive heart failure.

The data were presented today by Saibal Kar, M.D., director of interventional cardiac research at Cedars-Sinai Medical Center, Los Angeles, CA and the lead enrolling investigator of the EVEREST II trial. The EVEREST II study was designed to evaluate the MitraClip(R) system for the treatment of MR.

This data included 34 patients from the high-risk registry with moderate-to-severe (3+) or severe (4+) functional mitral regurgitation who received a MitraClip(R) device and had matched core laboratory echocardiographic data at baseline and 12 months. Results included a mean MR grade reduction from 3.2+/-0.5 at baseline to 1.8+/-0.9 at 12 months. In addition to the reduction of MR, there was significant reduction in the systolic and diastolic septo-lateral mitral annular diameter as well as a significant reduction in left ventricular end diastolic and systolic volumes. Left ventricular ejection fraction (LV EF) did not change significantly from baseline, while forward stroke volume (FSV) improved, indicating improved cardiac efficiency. Results were as follows:

Baseline and 1 year echocardiographic results

                                           Baseline      1 year       p-value
                                           --------      ------       -------
    MR (n=34)                              3.2+/-0.5    1.8+/-0.9
'/>"/>
SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. First Patients Treated in Italy With the Percutaneous MitraClip(R) System
2. First Dutch Patients Treated With the Percutaneous MitraClip(R) System
3. First Patients Enrolled in the Access-Europe Study of The MitraClip(R) Therapy
4. First 100 Patients Treated in Europe with the MitraClip(R) System for Percutaneous Mitral Repair
5. EVEREST Data Demonstrates Acute Reduction of Mitral Regurgitation Without Procedural Mortality in Patients Treated With the MitraClip(R) Therapy
6. First Swedish Patients Receive MitraClip(R) Therapy
7. Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009
8. Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve Repair
9. MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation
10. Vision restoration therapy shown to improve brain activity in brain injured patients
11. HIV therapy in pregnancy-data support WHO recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 29, 2014 “China Surgical ... data on the China Surgical Generators market. The ... volume (in units) and average prices (in US ... Generators, Ultrasonic Generators and Argon Plasma Coagulation Generators. ... distribution shares data for each of these market ...
(Date:7/28/2014)... Heights, MI (PRWEB) July 28, 2014 ... UHY, introduces the latest edition of UHY International Business ... provided by our members, on the most current business ... around the world. Issue 29 covers the following topics:, ... growth: Which industry sectors will thrive over the next ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... July 28, 2014 Thousands of DePuy ... behalf of individuals who were allegedly injured by a ... to move forward in U.S. District Court, Northern District ... Order issued on July 18, 2014, U.S. District Judge ... by the Plaintiffs’ Steering Committee that sought the deposition ...
(Date:7/28/2014)... Ticket Down is a dependable source for cheap ... the Sun Life Stadium in early September. The decades ... has is one that has continues to go on. With ... a consistent basis. The rivalry between South America nations, ... 2014 World Cup. To the delight of soccer aficionados ...
Breaking Medicine News(10 mins):Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3
... , ... on COPD and Immuno-Therapeutic Cancer Treatment , ... San Diego, CA (PRWEB) November 10, 2009 -- Entest BioMedical, ... immuno-therapeutic treatment of cancer and Chronic Obstructive Pulmonary Disease (COPD) and their potential to ...
... LOS ANGELES, Nov. 10 Research conducted by the Center ... on the effects of a popular form of hyperbaric oxygen ... The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with ... at 1.3 atmospheres of pressure, does not have a significant ...
... , ... At a time when health is a major concern for ... Pha-max, an internationally recognized company, has opened its doors in the United ... about their health and what better time to have options than now. ...
... , ... Advanced Vibration Exercise), a North American company, is expanding its cutting edge vibration exercise ... revolutionary vibration platforms, the Pro Elite, Air Reflex and Contour Plus, are now available ... ...
... ... child and family therapy pioneer B. Bryan Post is creating content ... emotional development for Miracle Industries, LLC., makers of the world-famous swadder ... will offer a valuable online resource for parents as well as ...
... Patrick, and Lieutenant Governor Murray , BOSTON, Nov. 9 ... P. McGovern (D-Worcester) called for all of the state,s hospitals ... their care. , "With 554,000 people in Massachusetts now ... Memorial Health Care in Worcester, "we have a problem that ...
Cached Medicine News:Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 2Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 3Health News:Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism 2Health News:Major Biotechnology Franchise Company Expands Rapidly Throughout the USA Amidst Mounting Health Concerns 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 3Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 4Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
... PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced ... for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced ... in vivo antitumor activity and a favorable safety ... in clinical development. The trials will be performed ...
... Feb. 7, 2011 Pharmasset, Inc. (Nasdaq: ... discovering, developing, and commercializing novel drugs to treat viral ... the quarter ended December 31, 2010. ... ended December 31, 2010 compared to $0.3 million for ...
Cached Medicine Technology:PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
Medicine Products: